ArticleClinical ophthalmology (Auckland, N.Z.)2026
Short-Term Visual and Optical Performance of the ZEISS CT LUCIA 621P Intraocular Lens Across Different Power Ranges.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the short-term efficacy and optical performance of the ZEISS CT LUCIA 621P intraocular lens (IOL) in cataract patients using a diopter (D)-stratified approach. Patients and Methods: This retrospective study included 304 eyes of 216 patients who underwent phacoemulsification with CT LUCIA 621P implantation. Eyes were stratified into four groups by implanted IOL power: Group 1 (<20.0 D, n=49), Group 2 (20.0-21.5 D, n=137), Group 3 (22.0-23.5 D, n=60), and Group 4 (≥24.0 D, n=58). Primary outcomes were monocular and binocular photopic/mesopic defocus curves and internal higher-order aberrations (HOAs) at 1 and 3 months because these directly evaluate the optical quality and depth of focus delivered by the non-constant aspheric ZEISS Optic design-the core innovative feature of the CT LUCIA 621P IOL-across the full spectrum of implanted powers. Secondary outcomes provide complementary clinical efficacy data; uncorrected and corrected distance visual acuity (UDVA/CDVA), uncorrected intermediate (UIVA) and near (UNVA), refractive predictability, and contrast sensitivity (CS). Analyses used generalized estimating equations (GEE) with an exchangeable correlation structure. Results: All groups achieved excellent refractive predictability with convergence of spherical equivalent (SE) toward emmetropia (p=0.398). Mean monocular UDVA at 3 months was comparable across groups (p=0.498). Monocular and binocular UIVA and UNVA were also comparable (all p>0.23). Photopic and mesopic defocus curves showed similar depth of focus across groups (p>0.05 at most levels). Postoperative spherical aberration (SA) and coma remained low with no significant inter-group differences after generalized GEE adjustment (p>0.17). Photopic CS was comparable across IOL power groups at most spatial frequencies. Conclusion: The CT LUCIA 621P IOL demonstrated consistent refractive predictability, VA across distances, and optical quality across a wide range of implanted powers, supporting its reliable use in contemporary cataract surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.